Chengdu Brilliant Biopharmaceutical Co., Ltd.

Has Chengdu Brilliant Biopharmaceutical Co., Ltd. received an FDA warning letter about GLP-1 drugs?

Yes. FDA issued Chengdu Brilliant Biopharmaceutical Co., Ltd. a warning letter naming semaglutide, dated Sep 11, 2025, with the FDA subject line “CGMP/Finished Pharmaceuticals/Adulterated.”

FDA records in this index name Chengdu Brilliant Biopharmaceutical Co., Ltd. on Sep 11, 2025.

Type named in FDA records
Not stated
FDA warning letters
1
Drug recall reports
0
Drugs named
Semaglutide
Latest record
Sep 11, 2025

FDA warning letters

Later letters FDA listsLetter
Sep 11, 2025CGMP/Finished Pharmaceuticals/AdulteratedSemaglutideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

FDA’s summary excerpts

Drug recalls

No openFDA drug recall reports in this index.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 1 product naming semaglutide under the labeler name “Chengdu Brilliant Biopharmaceutical Co., Ltd.”, matched to this company page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (1).

84524-451Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTAug 23, 2024None givenDec 31, 2026Unfinished drugs

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.